117 related articles for article (PubMed ID: 11032540)
1. [Safety and economic efficiency of platelet IIb/IIIa receptor blockers in acute coronary syndromes without ST-segment elevation].
Latour-Pérez J
Rev Esp Cardiol; 2000 Aug; 53(8):1148-50. PubMed ID: 11032540
[No Abstract] [Full Text] [Related]
2. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
Tricoci P; Peterson ED
J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
[TBL] [Abstract][Full Text] [Related]
3. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
4. [Glycoprotein IIB/IIIA receptor blockers as treatment of acute coronary syndromes and interventional cardiology].
Abramovitch N; Halon DA; Flugelman Y; Lewis BS
Harefuah; 1998 Jul; 135(1-2):41-7. PubMed ID: 10909532
[No Abstract] [Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
Elmouchi DA; Bates ER
Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
[TBL] [Abstract][Full Text] [Related]
6. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
MacCallum EM; Hanlon SJ; Byrne KH
Dimens Crit Care Nurs; 2000; 19(3):14-9. PubMed ID: 11998001
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Maree A; Fitzgerald D
Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
[No Abstract] [Full Text] [Related]
8. Safety of the use of IIb/IIIa receptor blockers with or without the use of other anticoagulants.
Ferguson JJ; Lau TK
Semin Interv Cardiol; 1999 Jun; 4(2):97-102. PubMed ID: 10473879
[No Abstract] [Full Text] [Related]
9. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
10. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa blockers in non-ST elevation acute coronary syndromes: only for well defined subgroups or a therapeutic option for all patients?
Verheugt FW
J Thromb Thrombolysis; 2003 Apr; 15(2):81-4. PubMed ID: 14618073
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
14. [Glycoprotein 2b3a inhibitors for acute coronary syndromes: what the trials tell us].
Elian D; Guetta V
Harefuah; 2003 May; 142(5):350-4, 398. PubMed ID: 12803058
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
[TBL] [Abstract][Full Text] [Related]
16. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?
Jackson G
Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219
[No Abstract] [Full Text] [Related]
17. [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes].
Sitges M; Bosch X; Sanz G
Rev Esp Cardiol; 2000 Mar; 53(3):422-39. PubMed ID: 10712972
[TBL] [Abstract][Full Text] [Related]
18. [Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Which, when, how?].
Juárez Herrera U
Arch Cardiol Mex; 2001; 71 Suppl 1():S85-90. PubMed ID: 11565353
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
Maree A; Fitzgerald DJ
Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
[TBL] [Abstract][Full Text] [Related]
20. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
